After three recent outbreaks of carbapenem-resistant Enterobacteriaceae cast a light on the dangers associated with multi-drug-resistant infections, Nanosphere Inc, Northbrook, Ill, recently reaffirmed the clinical benefits of its Verigene gram-negative blood culture test (BC-GN).

“The recent outbreaks of CRE at multiple institutions in the United States illustrate the unfortunate spread and associated need for rapid and accurate diagnostics,” says Michael McGarrity, Nanosphere CEO. “Supported by the recent call to action by the Centers for Disease Control and Prevention (CDC) to advance antibiotic stewardship and use of diagnostic tests, Nanosphere stands uniquely positioned to address this critical healthcare challenge.”

Cleared by FDA in June 2014, the Verigene BC-GN test is the only FDA-cleared test that rapidly identifies the five carbapenem-resistant genes most commonly associated with CRE, popularly known as “superbugs.” The test is said to detect CRE days faster than current testing methods, which the company believes may enable clinicians to optimize treatment of patients.

Across three U.S. medical centers, the recent CRE outbreaks reportedly led to two deaths and affected nearly 300 patients. CDC notes that 48 states have had confirmed cases of CRE infection.

For more information, visit Nanosphere.